Young-Dong Yu1, Dong-Sik Kim2, Geon-Young Byun1, Jeong-Hyeon Lee3, In-Sun Kim3, Chung-Yun Kim1, Young-Chul Kim1, Sung-Ock Suh1. 1. Department of Surgery, Division of HBP Surgery & Liver Transplantation, Korea University Medical Center, Korea University College of Medicine, Seoul, Korea. 2. Department of Surgery, Division of HBP Surgery & Liver Transplantation, Korea University Medical Center, Korea University College of Medicine, Seoul, Korea ; Department of Surgery, Division of Hepatobiliary and Pancreas Surgery, Korea University Medical Center, Korea University Medical College, Seoul, Korea. 3. Department of Pathology, Korea University Medical Center, Korea University Medical College, Seoul, Korea.
Abstract
BACKGROUND: Primary hepatic lymphoma (PHL) is a very rare malignancy, and constitutes about 0.016 % of all cases of non-Hodgkin's lymphoma and is often misdiagnosed. The optimal therapy is still unclear and the outcomes are uncertain. Among PHLs, a primary hepatic low-grade marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) is extremely rare. METHODS: We present a case of primary hepatic lymphoma (MALT lymphoma) treated with surgical resection and adjuvant chemotherapy. A 38-year-old Korean man, who was diagnosed with chronic hepatitis B 20 years ago, was admitted for liver biopsy after liver lesions were detected on follow-up computed tomography scan (CT). Liver biopsy revealed the diagnosis of marginal zone B-cell malignant lymphoma (MALT lymphoma). The preoperative clinical staging was IE, given that no additional foci of lymphoma were found anywhere else in the body. The patient underwent left hemihepatectomy. Subsequently, the patient received two cycles of CHOP (cyclophosphamide, adriamycin, vincristine, and prednisone) regimen. RESULTS: After 15 months of follow-up, the patient is alive and well without any evidence of disease recurrence. CONCLUSION: Although the prognosis is variable, good response to early surgery combined with postoperative chemotherapy can be achieved in strictly selected patients.
BACKGROUND:Primary hepatic lymphoma (PHL) is a very rare malignancy, and constitutes about 0.016 % of all cases of non-Hodgkin's lymphoma and is often misdiagnosed. The optimal therapy is still unclear and the outcomes are uncertain. Among PHLs, a primary hepatic low-grade marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) is extremely rare. METHODS: We present a case of primary hepatic lymphoma (MALT lymphoma) treated with surgical resection and adjuvant chemotherapy. A 38-year-old Korean man, who was diagnosed with chronic hepatitis B 20 years ago, was admitted for liver biopsy after liver lesions were detected on follow-up computed tomography scan (CT). Liver biopsy revealed the diagnosis of marginal zone B-cell malignant lymphoma (MALT lymphoma). The preoperative clinical staging was IE, given that no additional foci of lymphoma were found anywhere else in the body. The patient underwent left hemihepatectomy. Subsequently, the patient received two cycles of CHOP (cyclophosphamide, adriamycin, vincristine, and prednisone) regimen. RESULTS: After 15 months of follow-up, the patient is alive and well without any evidence of disease recurrence. CONCLUSION: Although the prognosis is variable, good response to early surgery combined with postoperative chemotherapy can be achieved in strictly selected patients.
Authors: R D Page; J E Romaguera; B Osborne; L J Medeiros; J Rodriguez; L North; C Sanz-Rodriguez; F Cabanillas Journal: Cancer Date: 2001-10-15 Impact factor: 6.860